Table 2.

Levels of nasal immunological markers gene expression at enrollment and after 48 h of treatment.

Cytokine median (range)	Linfovir		Placebo
	Enrollment	48 h	Enrollment	48 h
CCL2	1.39 (0.03–62.43)	1.96 (0.05–138.7)	3.13 (0.01–283.4)	1.59 (0.05–47.24)
CCL5	0.88 (0.05–17.43)	1.56 (0.02–21.87)	1.28 (0.11–13.66)	0.78 (0.06–4.66)
IL-8	2.41 (0.07–287.6)	4.24 (0.07–70.74)	3.57 (0.09–56.51)	4.65 (0.05–124.8)
IL-6	1.51 (0.06-155-3)	2.89 (0.01–83.30)	2.37 (0.06–413.7)	1.23 (0.03-62-95)
CXCL10	0.8 (0.02–118.1)	0.41 (0.01–164.7)	1.04 (0.01–163.2)	0.21 (0.0–8.95)
TLR2	1.61 (0.27–16)	3.11 (0.21–16.66)	1.34 (0.35–60.19)	2.12 (0.25–15.97)

Fold change for each gene is expressed as 2-ΔΔCt.